Adaptive viewing distance in super multi-view displays using aperiodic 3-D pixel location and dynamic view indices

This clip proves the feasibility of the proposed method for a viewing-lobe-free SMV 3D display when a viewer is horizontally moving in a practical environment

Adaptive viewing distance in super multi-view displays using aperiodic 3-D pixel location and dynamic view indices

This clip proves the feasibility of the proposed method for a viewing- lobe -free SMV 3D display when a viewer is depth-directionally moving in a practical environment

Adaptive viewing distance in super multi-view displays using aperiodic 3-D pixel location and dynamic view indices

This clip shows the composition of the test contents and its directional images perceptually observed in the test displays when a built-in stereo camera moves horizontally

Adaptive viewing distance in super multi-view displays using aperiodic 3-D pixel location and dynamic view indices

This clip shows the details of experimental setups and real-time performance of the proposed method. Although flipping images start to be shown at the front bound of the original SMV display, those are disappeared in the modified SMV display by the proposed method

Adaptive viewing distance in super multi-view displays using aperiodic 3-D pixel location and dynamic view indices

This clip proves the feasibility of the proposed method for a viewing- lobe -free SMV 3D display when a viewer is vertically moving in a practical environment

Characteristics of the two selected groups according to vitamin B₁₂ deficiency.

<p>The data are presented as the means (SD) or n (%).^*Hb<13 g/dL for men and <12 g/dL for women (WHO guidelines); BMI, body mass index; H2 blocker, histamine 2 receptor blocker; PPI, proton pump inhibitor; FBS, fasting blood sugar; TC, total cholesterol; TG, triglyceride; MCV, mean corpuscular volume; fL, femtoliter.</p><p>Characteristics of the two selected groups according to vitamin B₁₂ deficiency.</p

Characteristics of the subjects according to combination treatment with metformin.

<p>The data are presented as the means (SD) or n (%).^*Hb<13 g/dL for men and <12 g/dL for women (WHO guidelines); BMI, body mass index; H2 blocker, histamine 2 receptor blocker; PPI, proton pump inhibitor; FBS, fasting blood sugar; TC, total cholesterol; TG, triglyceride; MCV, mean corpuscular volume; fL, femtoliter.</p><p>S+M: Metformin + Sulfonylurea; I+M: Metformin + Insulin.</p><p>Characteristics of the subjects according to combination treatment with metformin.</p

Baseline clinical characteristics of the subjects.

<p>The data are shown as the means (SD) or n (%). ^*Hb<13 g/dL for men and <12 g/dL for women (WHO guidelines); BMI, body mass index; H2 blocker, histamine 2 receptor blocker; PPI, proton pump inhibitor; FBS, fasting blood sugar; TC, total cholesterol; TG, triglyceride; MCV, mean corpuscular volume; fL, femtoliter.</p><p>Baseline clinical characteristics of the subjects.</p

Logistic regression analysis for potential risk factors of Vitamin B₁₂ deficiency among patients with type 2 diabetes.

<p>Logistic regression analysis for potential risk factors of Vitamin B₁₂ deficiency among patients with type 2 diabetes.</p

The mean value of vitamin B₁₂ according to daily sulfonylurea dosage (* <i>P</i><0.05 vs. Group 1).

<p><b>Group 1</b>: glimepiride 1 mg, gliclazide 80 mg, gliclazide MR 30 mg, and glibenclamide 5 mg (n = 40); <b>Group 2</b>: glimepiride 2 mg, gliclazide 160 mg, gliclazide MR 60 mg, and glibenclamide 10 mg (n = 116); <b>Group 3</b>: glimepiride 3 mg, gliclazide 240 mg, gliclazide MR 90 mg, and glibenclamide 15 mg (n = 56); and <b>Group 4</b>: glimepiride 4 mg, gliclazide 320 mg, gliclazide MR 120 mg, and glibenclamide 20 mg (n = 87).</p